

Supplementary Table 2. IR, IRR, and IRD comparing 2 versus 3 dose vaccination by age at vaccination initiation and time between dose 1 and 2.

Age at first vaccination	Number of doses	Time between dose 1 and 2 (months)	IR, 95%CI*	P-value	IRR, 95%CI	P-value	IRD, 95%CI*	P-value
≤16yr	3 doses	Overall (0-3;4-7;8+)	64 (55;72)	<0.001	Reference	Reference	Reference	Reference
	2 doses	0-3	123 (90;156)	<0.001	1.92 (1.42;2.60)	<0.001	59 (25;93)	0.001
		4-7	79 (24;133)	0.005	1.23 (0.61;2.49)	0.562	15 (-40;70)	0.598
		8+	270 (70;470)	0.008	4.22 (1.99;8.94)	<0.001	206 (6;406)	0.044
17-19yr	3 doses	Overall (0-3;4-7;8+)	127 (106;149)	<0.001	Reference	Reference	Reference	Reference
	2 doses	0-3	242 (190;294)	<0.001	1.9 (1.48;2.45)	<0.001	115 (62;168)	<0.001
		4-7	95 (19;172)	0.015	0.75 (0.33;1.69)	0.484	-32 (-110;46)	0.422
		8+	374 (72;675)	0.015	2.93 (1.3;6.61)	0.009	246 (-54;547)	0.108

* IR, IRD reported per 100 000 person-years, reference groups: ≤16yr with 3 doses of qHPV (no time restriction between dose 1 and 1 and dose 2 and 3) and 17-19yrs with 3 doses of qHPV (no time restriction between dose 1 and 1 and dose 2 and 3).